Can-Fite BioPharma Ltd.
Reinhold Cohn House
P.O.Box: 4060
Tel Aviv
Tel: 03-7109330
Fax: 03-5606405
Email: dieliasoof@rcip.co.il
418 articles about Can-Fite BioPharma Ltd.
-
Namodenoson Treatment for Pancreatic and Liver Cancer: Data will be Discussed in Out-licensing and Distribution Partnering Meetings at Bio Europe Conference
3/11/2024
Can-Fite BioPharma Ltd. announced its VP of Business Development, Dr. Sari Fishman, will present data from the pancreatic and liver cancer programs during numerous partnering meetings at the BIO-Europe Spring 2024 in Barcelona, Spain, on Mar 18-27, 2024.
-
Can-Fite Broadens its Strong Intellectual Property (IP) for NASH: Received Patent Allowance in Canada
2/28/2024
Can-Fite BioPharma Ltd today announced it received a Notice of Allowance from the Canadian Intellectual Property Office for its patent application titled “An A3 Adenosine Receptor Ligand For Use In Treating Ectopic Fat Accumulation”.
-
Can-Fite Expands the Out-Licensing Deal with Ewopharma to Include the Pancreatic Cancer Indication
1/30/2024
Can-Fite BioPharma Ltd today announced that it has expanded its out licensing transaction with Ewopharma AG. to include the pancreatic cancer indication of Can-Fite.
-
Can-Fite: Top Scientific Journal Published Positive Data from the COMFORT-1 Phase III Psoriasis Study
1/29/2024
Can-Fite BioPharma Ltd. announced that the Journal of the European Academy of Dermatology and Venereology published an article.
-
The Anti-Obesity Effect of Can-Fite’s Namodenoson: Molecular Mechanism of Action in Pre-clinical and Human Studies
12/20/2023
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, reported new data on Namodenoson’s anti-obesity mechanism of action.
-
Can-Fite Received FDA Positive Response to Psoriasis Pediatric Plan
12/18/2023
FDA encouraged the Company to accelerate enrollment of adolescent patients due to Piclidenoson’s good safety profile.
-
Can-Fite’s Namodenoson for the Treatment of Pancreatic Cancer Patients: Progress in Clinical Development
12/4/2023
Can-Fite BioPharma Ltd. today announced that it completed the design of a Phase IIa study protocol for the treatment of patients with pancreatic cancer and plans to submit the protocol shortly to ethical committees for approval.
-
Can-Fite Reports Third Quarter 2023 Financial Results and Clinical Update
11/30/2023
Can-Fite BioPharma Ltd. announced financial results for the nine months ended September 30, 2023.
-
Can-Fite: Complete Response and 6.9 Years Overall Survival in a Patient with Advanced Liver Cancer Treated with Namodenoson
11/21/2023
Can-Fite BioPharma Ltd. announced that a patient who participated in the Phase II Liver Cancer Study and was treated with namodenoson has a complete response and overall survival of 6.9 years.
-
Can-Fite Announces Exercise of Warrants for Approximately $3.0 Million in Gross Proceeds
11/21/2023
Can-Fite BioPharma Ltd. announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 1,963,637 American Depositary Shares, having exercise prices ranging from $6.00 to $5.50 per ADS, issued by Can-Fite in December 2021 and January 2023, at a reduced exercise price of $1.53 per share.
-
Can-Fite Issues Business Update: All Clinical Programs and Business Development Activities Remain Solidly on Track
11/1/2023
Can-Fite BioPharma Ltd today confirmed that all of the Company’s clinical and business development activities are ongoing and proceeding by both its Israeli and US based staff.
-
Can Fite: Namodenoson Inhibits Pancreatic Carcinoma Published in Leading Scientific Journal; Robust anti-Cancer Effect & Molecular Mechanism of Action
10/30/2023
Can-Fite BioPharma Ltd. announced that Biomolecules, a peer-reviewed scientific journal focused on function and mechanism of bioactive molecules, published an article titled “Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways”, authored by Can-Fite’s CSO Dr. Pnina Fishman and others.
-
Can-Fite to Harness Artificial Intelligence to Develop Novel Anti-Cancer Drugs
10/26/2023
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology and inflammatory diseases, announced that it entered into an agreement with Collaborations Pharmaceuticals, Inc. to develop anti-cancer drugs utilizing artificial intelligence and machine learning techniques.
-
Can-Fite to Share its Rare Genetic Disease Lowe Syndrome Novel Treatment with Orphan Drug Japanese Companies
10/9/2023
Can-Fite BioPharma Ltd. announced that the Company’s Director of Business Development Dr. Sari Fishman will conduct virtually one-on-one meetings with Japanese companies specializing in the development of Orphan Drugs, at the BioJapan Conference held from October 11-13, 2023, in Yokohama, Japan.
-
Can-Fite Novel Approach for the Treatment of Pancreatic Carcinoma with Namodenoson Receives Appreciation of the American Association of Cancer Research (AACR)
9/27/2023
Can-Fite BioPharma Ltd today announced that its study titled “Namodenoson Inhibits the Growth of Pancreatic Carcinoma via De-regulation of the Wnt/β-catenin Signaling Pathway” has been accepted for a poster presentation at the AACR Special Conference on Pancreatic Cancer, held from September 27-30, 2023, in Boston, Massachusetts.
-
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference
9/7/2023
Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference.
-
Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies
8/31/2023
Can-Fite BioPharma Ltd., a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncology, inflammatory and liver diseases, announced financial results for the six months ended June 30, 2023.
-
Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome
8/24/2023
Can-Fite BioPharma Ltd. announced it plans to develop its lead drug candidate, Piclidenoson, for the treatment of Lowe Syndrome based on recent efficacy findings by Dr. Antonella De Matteis, Professor of Biology, Department of Molecular Medicine and Medical Biotechnology at the University of Naples Federico II, and Program Coordinator of the Cell Biology and Disease Mechanisms at The Telethon Institute of Genetics and Medicine in Italy.
-
Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis
8/18/2023
Can-Fite BioPharma Ltd today announced that it submitted a pediatric study plan to the U.S. Food and Drug Administration (FDA) for the treatment of adolescents suffering from psoriasis with Piclidenoson.
-
Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation
7/17/2023
Can-Fite’s novel approach for the treatment of advanced liver cancer will be presented at the American Society of Clinical Oncology (ASCO) Breakthrough Meeting in Japan on August 4th 2023.